home / stock / hepa / hepa news

HEPA News and Press, Hepion Pharmaceuticals Inc. From 01/09/23

Stock Information
Company Name: Hepion Pharmaceuticals Inc.
Stock Symbol: HEPA
Market: NASDAQ
Website: hepionpharma.com
Menu
HEPA HEPA Quote HEPA Short HEPA News HEPA Articles HEPA Message Board
Get HEPA Alerts

News, Short Squeeze, Breakout and More Instantly...
HEPA - Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding

EDISON, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steato...
HEPA - Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023

EDISON, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steato...

HEPA - Hepion Pharmaceuticals, Inc. Granted 180-day Extension by Nasdaq to Meet the Minimum Bid Price Requirements

EDISON, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steato...

HEPA - Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 'ALTITUDE-NASH' Liver Function Trial

– Hepion Enrolls 60 F3 NASH Subjects in only 12 weeks, facilitated by AGILE 3+ non-invasive test – – Hepion, Summit Clinical Research, and HepQuant Align to Deliver Rencofilstat’s Hepatic Function and NASH Biomarker Results by Q2, 2023 – EDISON...
HEPA - Hepion Pharmaceuticals to Present Rencofilstat's Poly-Indication Potential at the 6th Annual Antifibrotic Drug Development Summit

EDISON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic ...

HEPA - Hepion Pharmaceuticals dips after pricing $20M convertible preferred stock offering

Hepion Pharmaceuticals ( NASDAQ: HEPA ) has priced a $20M private offering of convertible redeemable preferred stock. The biopharmaceutical company entered into a securities purchase agreement with certain institutional investors to purchase 1.9M shares of Series F convert...

HEPA - Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock

EDISON, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic ...
HEPA - Hepion Pharmaceuticals to Present Two Posters at Upcoming AASLD The Liver Meeting® 2022

EDISON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic ...

HEPA - Hepion Pharmaceuticals Announces Publication of Phase 2a 'AMBITION' Clinical Trial Results

- Study met safety, tolerability, and pharmacokinetics primary endpoints - - Reductions in ALT, ProC3, and C6M suggest direct antifibrotic effects with longer treatment duration - - Enrollment initiated in Phase 2b ‘ASCEND-NASH’ trial evaluating the safety ...

HEPA - Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat

EDISON, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...
Previous 10 Next 10